IgA Vasculitis as a Potential Complication of Fourth-Line Chemotherapy with Tegafur/Gimeracil/Oteracil (S-1) in Advanced Non-Small Cell Lung Cancer: A Case Report

Ryotaro Yoneoka; Hajime Kasai; Aoi Hino; Ayumi Hayashi; Atsushi Sasaki; Masayuki Ota; Katsuhiko Asanuma; Takuji Suzuki

doi:10.12659/AJCR.941826

28 December 2023 : Case report Japan

IgA Vasculitis as a Potential Complication of Fourth-Line Chemotherapy with Tegafur/Gimeracil/Oteracil (S-1) in Advanced Non-Small Cell Lung Cancer: A Case Report

Rare coexistence of disease or pathology

Ryotaro Yoneoka^1ABCDEF, Hajime Kasai^234ABCDEF*, Aoi Hino^2ABCDE, Ayumi Hayashi^5BCDE, Atsushi Sasaki^2BCDE, Masayuki Ota^6BCDE, Katsuhiko Asanuma^5DE, Takuji Suzuki^2DE

DOI: 10.12659/AJCR.941826

Am J Case Rep 2023; 24:e941826

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 3. The clinical course of the patient. (A) Timeline of events. (B) Chest radiograph and computed tomography scans obtained on the dates indicated in the timeline above. (C) Serum creatinine and albumin levels over time. Alb – albumin; CBDCA – carboplatin; Cre – creatinine; IgA – immunoglobulin; nab-PTX – nab-pacritaxicel; S-1 – tegafur/gimeracil/oteracil.

Back to the Article

IgA Vasculitis as a Potential Complication of Fourth-Line Chemotherapy with Tegafur/Gimeracil/Oteracil (S-1) in Advanced Non-Small Cell Lung Cancer: A Case Report

Your Privacy